SOPHiA GENETICS (SOPH) director receives RSU and option grants as equity pay

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.

Insights

Equity compensation analyst

Routine director equity grants, no open‑market buying or selling.

Director Vincent Ossipow received equity awards from SOPHiA GENETICS SA on June 18, 2026. He acquired 19,724 RSUs and 28,818 share options with a $5.46 exercise price as compensation, not through market transactions.

The filing shows these RSUs and options vest fully at the next annual shareholder meeting, contingent on continued service. This structure aligns director incentives with shareholders over the near term but does not signal a view on current valuation, since no shares were bought or sold in the market.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ossipow Vincent

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	28,818	$5.46	$157K
Grant/Award	Ordinary Shares	19,724	$5.46	$108K

Holdings After Transaction: Share Option (Right to Buy) — 138,569 shares (Direct, null); Ordinary Shares — 522,860 shares (Direct, null)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Key Figures

RSU grant: 19,724 units Option grant size: 28,818 options Option exercise price: $5.46 per share +3 more

6 metrics

RSU grant 19,724 units RSUs granted June 18, 2026

Option grant size 28,818 options Share options granted June 18, 2026

Option exercise price $5.46 per share Exercise price for new options

Shares held after grant 522,860 shares Direct ordinary shares following transactions

Options held after grant 138,569 options Total options following transactions

Option expiration June 18, 2036 Expiration date of granted options

Key Terms

restricted stock unit ("RSU"), share options, exercise price, vesting

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share"

share options financial

"The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

exercise price financial

"conversion_or_exercise_price": "5.4600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:02 PM Accepted by SEC EDGAR 06/22/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ossipow Vincent

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/18/2026		A		19,724(1)	A	$5.46	522,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.46	06/18/2026		A		28,818		(2)	06/18/2036	Ordinary Shares	28,818	$5.46	138,569	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Vincent Ossipow	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Vincent Ossipow receive from SOPHiA GENETICS (SOPH)?

Vincent Ossipow received 19,724 restricted stock units and 28,818 share options from SOPHiA GENETICS. Each RSU equals one ordinary share, and the options give him the right to buy ordinary shares at a fixed exercise price.

What is the exercise price of Vincent Ossipow’s new SOPHiA GENETICS options?

The new share options granted to Vincent Ossipow have an exercise price of $5.46 per share. This means he can purchase ordinary shares at $5.46 once the options vest, regardless of the future market price of SOPHiA GENETICS shares.

When do Vincent Ossipow’s RSUs and options from SOPHiA GENETICS vest?

Both the 19,724 RSUs and the 28,818 share options vest 100% on the date of SOPHiA GENETICS’ next scheduled annual shareholder meeting. Vesting is conditional on Ossipow’s continued service with the company through that meeting date.

How many SOPHiA GENETICS shares does Vincent Ossipow hold after these grants?

After the June 18, 2026 awards, Vincent Ossipow directly holds 522,860 ordinary shares of SOPHiA GENETICS. In addition, he holds 138,569 share options, which represent rights to acquire more shares if he chooses to exercise them after vesting.

Were Vincent Ossipow’s SOPHiA GENETICS transactions open‑market buys or sales?

The transactions were compensation-related grants, not open‑market trades. The filing classifies them with transaction code “A” for awards, and notes they are RSU and option grants contingent on continued service, so no market buying or selling took place.